Loading clinical trials...
Loading clinical trials...
SWE-NEO: Swedish NeoAdjuvant Trial Comparing Anti-PD-1 Monotherapy to Combined Anti-CTLA-4/Anti-PD-1 Blockade in Resectable Stage III Melanoma
Conditions
Interventions
Nivolumab
Nivolumab + Ipilimumab
Locations
3
Sweden
Sahlgrenska University Hospital
Gothenburg, Sweden
Skane University Hospital
Lund, Sweden
Karolinska University Hospital
Stockholm, Sweden
Start Date
July 10, 2025
Primary Completion Date
April 15, 2032
Completion Date
April 15, 2032
Last Updated
December 12, 2025
NCT03493230
NCT02977052
NCT01676779
Lead Sponsor
Hildur Helgadottir
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions